Development of mRNA vaccines and therapies

preview_player
Показать описание
BioNTech Co-Founder and CEO Prof Uğur Şahin, MD, discusses the scientific and technological hurdles that had to be overcome for the development of the COVID-19 vaccine partnership with Pfizer, as well as the basic properties of mRNA drugs and their mode of action.

A panel discussion follows with Prof Özlem Türeci, MD, Co-Founder and CMO of BioNTech, and Dr Ivan Đikić, Professor of Biochemistry at Goethe University in Frankfurt and a Fellow of the Max Planck Institute for Biophysics. They discuss examples of mRNA-based drug developments in preclinical and clinical trials and perspectives for the therapeutic use of mRNA for the treatment of cancer and autoimmune diseases, and they answer questions from the public. Richard Horton, FRCP FMedSci, Editor-in-Chief of The Lancet, is host and moderator.
Рекомендации по теме
Комментарии
Автор

Oh please ……
Are we awake yet …..
🕊🙏🏻🕊🙏🏻🕊🙏🏻🕊
One year later ……..

metgirl
Автор

It was very inspirational from many perspectives. Thank you for sharing such a great webinar with us!

tubasahin
Автор

Why is graphene oxide in the vaccine???

JohnAdams-muxd
Автор

Can someone translate the presentation so that non-experts can understand?

franzgatzweiler
Автор

I wonder if these people will be culpable for the deaths to come.... Tick Tock Tick Tock Tick Tock

JohnAdams-muxd